Research
Hormonal
The proportion of participants discontinuing treatment for any reason was lower with semaglutide (13.5%) compared to liraglutide (27.6%).
Semaglutide may lead to better treatment adherence compared to liraglutide.
StrongSupportsmedium confidence
Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide.
Why this rating
Based on a randomized, open-label, phase 3b trial design.
Source
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica M. Rubino et al. · JAMA · 2022
DOI 10.1001/jama.2021.23619
rct · n=338Cited 856×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly subcutaneous semaglutide resulted in a mean weight change of -15.8% compared to -6.4% with once-daily subcutaneous liraglutide at 68 weeks.Strong
- Participants had significantly greater odds of achieving 10% or more weight loss with semaglutide compared to liraglutide (70.9% vs 25.6%).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →